Heparin from bovine intestinal mucosa: Glycans with multiple sulfation patterns and anticoagulant effects

Summary

Pharmaceutical grade heparins from porcine intestine and bovine lung consist mainly of repeating tri-sulfated units, of the disaccharide →4-α-IdoA2S-1 →4-α-GlcNS6S-1 →. Heparin preparations from bovine intestine, in contrast, are more heterogeneous. Nuclear magnetic resonance (NMR) and disaccharide analysis after heparinase digestions show that heparin from bovine intestine contains α-glucosamine with significant substitutive variations: 64% are 6-O-sulfated and N-sulfated, as in porcine intestinal heparin while 36% are 6-desulfated. Desulfated α-iduronic acid units are contained in slightly lower proportions in bovine than in porcine heparin. NMR data also indicate N-, 3-and 6-trisulfated a-glucosamine (lower proportions) and α-GlcNS-1→4-α-GlcA and α-IdoA2S-1→4-α-GlcNAc (higher amounts) in bovine than in porcine heparin. Porcine and bovine heparins can be fractionated by anion exchange chromatography into three fractions containing different substitutions on the a-glucosamine units. Each individual fraction shows close disaccharide composition and anticoagulant activity, regardless of their origin (bovine or porcine intestine). However, these two heparins differ markedly in the proportions of the three fractions. Interestingly, fractions with the typical he-parin disaccharides of porcine intestine are present in bovine intestinal heparin. These fractions contain high in vitro anticoagulant activity, reduced antithrombotic effect and high bleeding tendency. These observations indicate that the prediction of haemostatic effects of heparin preparations cannot rely exclusively on structural analysis and anticoagulant assays in vitro. Minor structural components may account for variations on in vivo effects. In conclusion, we suggest that pharmaceutical grade bovine intestinal heparin, even after purification procedures, is not an equivalent drug to porcine intestinal heparin.

Keywords

Thrombosis - glycosaminoglycan - serpin - antithrombotic drug - bleeding tendency

• References

• 1 Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. ThombHaem 2008; 123: S29-S35.
• 2 Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2009; 26: 313-321.
• 3 Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 2000; 84: 1052-1056.
• 4 Aquino RS, Pereira MS, Vairo BC. et al. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs?. ThrombHaemost 2010; 103: 1005-1015.
• 5 Melo EI, Pereira MS, Cunha RS. et al. Heparin quality control in the Brazilian market: implications in the cardiovascular surgery. Rev Bras Cir Cardiovasc 2008; 23: 169-174.
• 6 Farndale RW, Buttle DJ, Barret AJ. Improved quantitation and discrimination of sulphatedglycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986; 883: 173-177.
• 7 Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962; 04: 330-334.
• 8 Castro MO, Pomin VH, Santos LL. et al. A unique 2-sulfated β-galactan from the egg jelly of the sea urchin Glyptocidariscrenularis: conformational flexibility versus induction of the sperm acrosome reaction. J Biol Chem 2009; 284: 18790-18800.
• 9 Alves CS, Mourão PAS. Interaction of high molecular weight chondroitin sulfate from human aorta with plasma low density lipoproteins. Atherosclerosis 1988; 73: 113-124.
• 10 Tovar AMF, Cesar DCF, Leta GC. et al. Age-related changes in populations of aortic glycosaminoglycans. ArteriosclerThrombVascBiol 1998; 18: 604-614.
• 11 Tovar AMF, de Mattos DA, Stelling M P. et al. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochimica Biophysica Acta 2005; 1740: 45-53.
• 12 Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and un-catalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-559.
• 13 Wessler S, Reimer SM, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J ApplPhysiol 1959; 14: 943-946.
• 14 Herbert JM, Bernat A, Maffrand J P. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286.
• 15 Casu B, Guerrini M, Naggi A. et al. Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arzneimittelforschung 1996; 46: 472-477.
• 16 Mascellani G, Liverani L, Bianchini P. Analysis of heparin origin by HPLC quanti-tation of disaccharide components. Farmaco 1996; 51: 247-254.
• 17 Guerrini M, Naggi A, Guglieri S. et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectro-scopy. Anal Biochem 2005; 337: 35-47.
• 18 Guerrini M, Guglieri S, Casu B. et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for ver y hig h affinity induced by an unusual glu-curonic acid residue. J Biol Chem 2008; 283: 26662-26675.
• 19 Melo FR, Mourão PAS. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
• 20 Fonseca RJ, Oliveira SN, Melo FR. et al. Slight differences in sulfation of algal gal-actans account for differences in their anticoagulant and venous antithrombotic activities. ThrombHaemost 2008; 99: 539-545.
• 21 Fonseca RJ, Santos GR, Mourão PA. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications. Thromb Haemost 2009; 102: 829-836.
• 22 Fonseca RJ, Oliveira SN, Pomin VH. et al. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010; 103: 994-1004.
• 23 Pacheco RG, Vicente CP, Zancan P. et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinolysis 2000; 11: 563-573.
• 24 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.